Clinical Trials Logo

Unresectable Carcinoma clinical trials

View clinical trials related to Unresectable Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03981614 Active, not recruiting - Clinical trials for Stage IV Colorectal Cancer AJCC v8

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Start date: October 29, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well binimetinib and palbociclib work compared to TAS-102 in treating patients with KRAS and NRAS mutation positive colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving binimetinib and palbociclib may work better compared to TAS-102 alone in treating patients with colorectal cancer.

NCT ID: NCT03941262 Completed - Clinical trials for Advanced Solid Tumor

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Start date: July 15, 2019
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent and in combination with avelumab or pembrolizumab, for the treatment of subjects with advanced and/or metastatic refractory cancer that has failed three or more prior lines of conventional standard of care therapy.